https://www.4sc.com/news/4sc-presents-at-annual-bio-ceo-and-investor-conference-2017/ 2017-03-15T08:57:28+00:00 https://www.4sc.com/news/4sc-202-a-promising-combination-partner-for-cancer-treatment/ 2017-03-21T13:04:15+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-29-march-2017-to-present-annual-results-2016/ 2017-03-22T06:30:24+00:00 https://www.4sc.com/news/4sc-announces-results-for-financial-year-2016/ 2017-03-29T05:30:34+00:00 https://www.4sc.com/news/new-mechanistic-insights-into-4sc-202s-epigenetic-mode-of-action/ 2017-04-18T13:07:41+00:00 https://www.4sc.com/news/4sc-informiert-ueber-q1-2017/ 2017-04-27T05:30:45+00:00 https://www.4sc.com/news/4sc-attending-3-upcoming-investor-and-scientific-conferences/ 2017-05-24T14:05:59+00:00 https://www.4sc.com/news/4sc-ag-progress-update-on-pivotal-resmain-study-of-resminostat-in-ctcl-at-13th-congress-of-the-eado/ 2017-05-29T11:01:34+00:00 https://www.4sc.com/news/resminostat-enhances-immune-cell-cancer-cell-interaction/ 2017-05-30T05:30:24+00:00 https://www.4sc.com/news/4sc-licenses-kv1-3-inhibitors-to-maruho/ 2017-07-18T05:30:32+00:00 https://www.4sc.com/news/4sc-ag-granted-a-fundamental-composition-of-matter-patent-for-4sc-208-for-the-us/ 2017-08-01T05:30:11+00:00 https://www.4sc.com/news/conference-call-to-be-hosted-on-10-august-2017-to-present-the-half-year-financial-report-2017/ 2017-08-03T05:30:51+00:00 https://www.4sc.com/news/4sc-provides-q2-and-6m-2017-update/ 2017-08-10T05:30:11+00:00 https://www.4sc.com/news/corporate-news-4sc-ag-announces-updated-and-progressive-development-program/ 2017-08-22T12:16:13+00:00 https://www.4sc.com/news/4sc-to-present-at-upcoming-scientific-conferences/ 2017-08-31T05:30:37+00:00 https://www.4sc.com/news/phase-i-study-of-4scs-resminostat-indicates-efficacy-in-biliary-tract-cancer/ 2017-09-13T05:30:51+00:00 https://www.4sc.com/news/4sc-to-present-supportive-preclinical-data-on-resminostats-potential-as-maintenance-therapy-for-ctcl/ 2017-10-06T14:22:13+00:00 https://www.4sc.com/news/resminostat-demonstrates-potential-to-significantly-alleviate-itching-in-ctcl-patients/ 2017-10-10T05:30:47+00:00 https://www.4sc.com/news/4sc-provides-q3-and-9m-2017-update/ 2017-10-26T05:30:44+00:00 https://www.4sc.com/news/10-upcoming-conferences-and-investor-events/ 2017-11-02T06:30:15+00:00 https://www.4sc.com/news/first-patient-enrolled-in-phase-ibii-study-sensitize-of-4sc-202-in-melanoma/ 2017-11-06T06:30:03+00:00 https://www.4sc.com/news/4sc-receives-milestone-payment-from-immunic/ 2017-12-13T06:30:41+00:00 https://www.4sc.com/news/significant-milestone-reached-for-pivotal-resmain-study-of-resminostat-as-maintenance-therapy-in-ctcl/ 2017-12-18T13:51:57+00:00 https://www.4sc.com/news/4sc-receives-pediatric-investigation-plan-waiver-for-resminostat-in-ctcl-from-the-european-medicines-agency/ 2017-12-20T06:30:15+00:00 https://www.4sc.com/news/11-upcoming-conferences-and-investor-events/ 2018-01-09T06:30:35+00:00 https://www.4sc.com/news/4sc-ag-strengthens-patent-protection-for-its-hedgehog-gli-signaling-inhibitor-4sc-208/ 2018-01-22T06:30:49+00:00 https://www.4sc.com/news/positive-dsmb-safety-review-of-4scs-pivotal-resmain-study-of-resminostat-in-ctcl/ 2018-01-31T06:30:00+00:00 https://www.4sc.com/news/4sc-ag-8-upcoming-conferences/ 2018-02-22T06:30:35+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-21-march-2018-to-present-the-financial-report-2017/ 2018-03-15T06:30:09+00:00 https://www.4sc.com/news/4sc-ag-secures-eur-41-million-from-successful-capital-increase/ 2018-03-19T10:21:56+00:00 https://www.4sc.com/news/4sc-ag-announces-subscription-price-for-new-shares-from-current-capital-increase/ 2018-03-19T10:24:47+00:00 https://www.4sc.com/news/4sc-ag-resolves-to-issue-new-shares-to-continue-to-advance-its-drug-development-programs-for-resminostat-4sc-202-and-4sc-208/ 2018-03-19T10:25:30+00:00 https://www.4sc.com/news/ad-hoc-announcement-4sc-ag-announces-updated-and-progressive-development-program/ 2018-03-19T10:26:26+00:00 https://www.4sc.com/news/4sc-ag-announces-results-for-financial-year-2017/ 2018-03-21T06:30:05+00:00 https://www.4sc.com/news/yakult-honsha-joins-4scs-pivotal-resmain-study-of-resminostat-in-ctcl-4sc-receives-milestone-payment/ 2018-03-27T05:30:27+00:00 https://www.4sc.com/news/yakult-honsha-recruits-first-japanese-patient-in-4scs-pivotal-resmain-study-of-resminostat-in-ctcl/ 2018-04-11T05:30:38+00:00 https://www.4sc.com/news/4sc-at-aacr-broadened-clinical-options-for-4sc-202/ 2018-04-17T05:30:26+00:00 https://www.4sc.com/news/phase-ii-study-of-4scs-resminostat-in-biliary-tract-cancer-in-japan-is-initiated/ 2018-04-19T05:30:02+00:00 https://www.4sc.com/news/4sc-provides-q1-2018-update/ 2018-04-26T05:30:45+00:00 https://www.4sc.com/news/4sc-ag-9-upcoming-conferences-and-roadshows/ 2018-05-22T05:30:58+00:00 https://www.4sc.com/news/new-data-supports-resminostats-mechanism-of-action-in-ctcl-maintenance-therapy/ 2018-06-28T05:30:55+00:00 https://www.4sc.com/news/positive-safety-review-of-4scs-phase-ib-ii-sensitize-study-of-domatinostat-4sc-202-pembrolizumab-in-melanoma/ 2018-07-03T05:30:38+00:00 https://www.4sc.com/news/stifel-nicolaus-europe-initiates-research-coverage-on-4sc-with-a-buy-rating/ 2018-07-18T05:30:54+00:00 https://www.4sc.com/news/first-patient-enrolled-in-2nd-dose-cohort-of-phase-ib-ii-study-sensitize-of-domatinostat-4sc-202-pembrolizumab-in-melanoma/ 2018-07-31T05:30:33+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-9-august-2018-to-present-the-half-year-report-2018/ 2018-08-02T05:30:46+00:00 https://www.4sc.com/news/4sc-provides-q2-and-h1-2018-update/ 2018-08-09T05:30:48+00:00 https://www.4sc.com/news/4sc-ag-fda-approves-ind-application-for-domatinostat-4sc-202-in-melanoma/ 2018-08-15T05:30:12+00:00 https://www.4sc.com/news/4sc-ag-6-upcoming-conferences-and-roadshows/ 2018-09-12T05:30:08+00:00 https://www.4sc.com/news/4sc-ag-domatinostat-plus-chemotherapy-overcoming-drug-resistance/ 2018-09-20T05:30:05+00:00 https://www.4sc.com/news/4sc-provides-q3-business-update-and-outlook/ 2018-10-25T05:30:47+00:00 https://www.4sc.com/news/4sc-receives-milestone-payment-from-link-health/ 2018-10-31T06:30:58+00:00 https://www.4sc.com/news/4sc-reaches-significant-milestone-with-enrollment-of-100-patients-in-pivotal-resmain-study-of-resminostat-as-ctcl-maintenance-therapy/ 2018-11-20T06:30:07+00:00 https://www.4sc.com/news/positive-safety-review-of-4scs-phase-ib-ii-sensitize-study-of-domatinostat-4sc-202-pembrolizumab-in-melanoma-2/ 2018-12-27T06:30:41+00:00 https://www.4sc.com/news/4scs-domatinostat-4sc-202-begins-phase-ii-gastrointestinal-cancer-clinical-trial/ 2019-01-14T06:30:35+00:00 https://www.4sc.com/news/4scs-pivotal-resmain-study-of-resminostat-in-ctcl-receives-second-positive-safety-review/ 2019-01-28T06:30:36+00:00 https://www.4sc.com/news/first-patient-enrolled-in-3rd-dose-cohort-of-phase-ib-ii-study-sensitize/ 2019-01-30T06:30:03+00:00 https://www.4sc.com/news/first-patient-enrolled-in-phase-ii-study-emerge-of-domatinostat-4sc-202-in-gastrointestinal-cancer/ 2019-02-06T06:30:31+00:00 https://www.4sc.com/news/4sc-ag-9-upcoming-conferences-and-roadshows-2/ 2019-03-07T06:30:20+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-20-march-2019-to-present-the-annual-report-2018/ 2019-03-13T06:30:45+00:00 https://www.4sc.com/news/4sc-ag-provides-results-for-financial-year-2018-and-outlook/ 2019-03-20T06:30:15+00:00 https://www.4sc.com/news/dynavaxs-sd-101-and-4scs-domatinostat-demonstrate-synergy-and-induce-a-systemic-anti-tumor-response-in-preclinical-models/ 2019-04-01T17:00:48+00:00 https://www.4sc.com/news/4sc-ag-domatinostats-mode-of-action-in-merkel-cell-carcinoma/ 2019-04-08T05:30:42+00:00 https://www.4sc.com/news/4sc-provides-q1-2019-update/ 2019-04-18T05:30:00+00:00 https://www.4sc.com/news/4sc-ag-4-upcoming-conferences/ 2019-05-16T05:30:57+00:00 https://www.4sc.com/news/4sc-ag-resolves-to-issue-new-shares-to-continue-to-advance-its-drug-development-programs-for-resminostat-and-domatinostat/ 2019-06-11T07:35:38+00:00 https://www.4sc.com/news/4sc-ag-announces-subscription-price-for-new-shares-from-current-capital-increase-2/ 2019-06-21T07:39:51+00:00 https://www.4sc.com/news/4sc-ag-secures-eur-11-million-from-capital-increase/ 2019-06-28T15:33:01+00:00 https://www.4sc.com/news/4sc-ag-positive-safety-review-of-phase-ib-ii-sensitize-study-of-domatinostat-pembrolizumab-in-melanoma/ 2019-07-11T05:30:57+00:00 https://www.4sc.com/news/4sc-ag-positive-safety-review-of-phase-ib-ii-emerge-study-of-domatinostat-avelumab-in-gastrointestinal-cancer/ 2019-07-25T05:30:18+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-8-august-2019-to-present-the-half-year-report-2019/ 2019-08-01T05:30:00+00:00 https://www.4sc.com/news/4sc-ag-provides-q2-and-h1-2019-update/ 2019-08-08T05:30:57+00:00 https://www.4sc.com/news/4sc-ag-8-upcoming-conferences-2/ 2019-08-28T05:30:41+00:00 https://www.4sc.com/news/4sc-ag-erhaelt-meilensteinzahlung-von-link-health-link-health-startet-klinische-phase-i-studie-mit-lh031-4sc-205-in-fortgeschrittenen-soliden-tumoren-oder-lymphomen/ 2019-09-12T12:03:59+00:00 https://www.4sc.com/news/4sc-ag-poster-presentations-at-esmo-congress/ 2019-09-22T22:05:36+00:00 https://www.4sc.com/news/pivotal-resmain-study-of-resminostat-in-ctcl-update-at-the-eortc-cltf-meeting-2019-in-athens/ 2019-09-27T05:30:08+00:00 https://www.4sc.com/news/key-resminostat-scientific-data-to-be-presented-at-eortc-cltf-meeting-in-athens/ 2019-09-27T05:30:47+00:00 https://www.4sc.com/news/first-domatinostat-combination-data-from-phase-ib-ii-sensitize-study-presented-at-esmo/ 2019-09-30T10:00:42+00:00 https://www.4sc.com/news/4sc-ag-resolves-to-issue-new-shares-santo-and-ats-undertake-to-subscribe-buy-the-new-shares/ 2019-10-07T15:00:02+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-17-october-2019-to-present-the-q3-announcement-2019/ 2019-10-10T05:30:46+00:00 https://www.4sc.com/news/4sc-and-netherlands-cancer-institute-collaborate-on-clinical-evaluation-of-domatinostat-in-the-neoadjuvant-setting-in-melanoma/ 2019-10-16T05:30:49+00:00 https://www.4sc.com/news/4sc-provides-q3-business-update-and-outlook-2/ 2019-10-17T05:30:23+00:00 https://www.4sc.com/news/4sc-ag-poster-presentation-at-1st-international-symposium-on-merkel-cell-carcinoma/ 2019-10-21T05:30:55+00:00 https://www.4sc.com/news/4sc-ag-secures-circa-eur-22-4-million-from-a-capital-increase/ 2019-11-12T13:15:48+00:00 https://www.4sc.com/news/4sc-ag-positive-safety-review-of-phase-ib-ii-emerge-study-of-domatinostat-avelumab-in-gastrointestinal-cancer-2/ 2019-12-13T06:30:03+00:00 https://www.4sc.com/news/4sc-ag-enters-into-avelumab-supply-agreement-with-merck-kgaa-darmstadt-germany-and-pfizer-for-clinical-combination-study-of-domatinostat-in-merkel-cell-carcinoma/ 2020-01-07T06:30:18+00:00 https://www.4sc.com/news/4sc-ag-3-upcoming-conferences/ 2020-01-09T06:30:05+00:00 https://www.4sc.com/news/first-patient-enrolled-in-donimi-study-evaluating-domatinostat-in-the-neoadjuvant-setting-in-melanoma/ 2020-01-15T06:30:05+00:00 https://www.4sc.com/news/4sc-resminostat-and-resmain-study-update/ 2020-01-31T06:30:51+00:00 https://www.4sc.com/news/4sc-to-present-at-the-world-congress-of-cutaneous-lymphomas-in-barcelona-spain/ 2020-02-12T06:30:02+00:00 https://www.4sc.com/news/4sc-ag-provides-results-for-financial-year-2019-and-outlook/ 2020-03-25T06:30:25+00:00 https://www.4sc.com/news/fda-accepts-ind-application-for-merklin-2-study/ 2020-04-08T05:30:57+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-21-april-2020-to-present-the-q1-report-2020/ 2020-04-16T05:30:58+00:00 https://www.4sc.com/news/4sc-provides-q1-2020-update/ 2020-04-21T05:30:41+00:00 https://www.4sc.com/news/4sc-ag-plans-extraordinary-general-meeting-and-reduction-of-share-capital/ 2020-06-17T06:16:17+00:00 https://www.4sc.com/news/4sc-signs-licensing-and-development-agreement-with-menarini-for-resminostat-in-asia-pacific-excluding-japan/ 2020-06-17T06:22:29+00:00 https://www.4sc.com/news/4sc-ag-plans-to-issue-new-shares-to-finance-the-further-development-of-its-epigenetic-lead-anti-cancer-compound-resminostat/ 2020-06-17T06:24:55+00:00 https://www.4sc.com/news/4sc-ag-announces-subscription-price-for-new-shares-from-current-capital-increase-3/ 2020-06-17T06:27:36+00:00 https://www.4sc.com/news/4sc-ag-secures-eur-29-million-from-capital-increase-to-finance-planned-clinical-development-programme-of-its-cancer-compound-resminostat/ 2020-06-17T06:45:03+00:00 https://www.4sc.com/news/chairman-of-the-management-board-enno-spillner-will-not-extend-his-current-term-of-office-but-will-leave-the-company-after-a-transitional-period-ending-30-june-2016/ 2020-06-17T07:09:50+00:00 https://www.4sc.com/news/4sc-sells-operations-of-its-discovery-division/ 2020-06-17T07:12:40+00:00 https://www.4sc.com/news/4sc-provides-headline-results-from-yakult-honshas-phase-ii-trial-of-resminostat-in-combination-with-sorafenib-as-first-line-therapy-in-liver-cancer/ 2020-06-17T07:19:53+00:00 https://www.4sc.com/news/dr-jason-loveridge-appointed-new-ceo-of-4sc/ 2020-06-17T07:23:08+00:00 https://www.4sc.com/news/subgroup-analysis-suggests-survival-benefit-in-patients-with-advanced-liver-cancer-treated-with-resminostat/ 2020-06-17T07:48:52+00:00 https://www.4sc.com/news/dr-daniel-vitt-to-step-down-as-cdo-cso-and-from-the-management-board-at-the-end-of-2016-dr-frank-hermann-promoted-to-cdo-and-dr-roland-baumgartner-to-cso/ 2020-06-17T07:50:56+00:00 https://www.4sc.com/news/press-release-prof-dr-helga-ruebsamen-schaeff-and-joerg-von-petrikowsky-join-the-supervisory-board-of-4sc-ag/ 2020-06-17T09:08:10+00:00 https://www.4sc.com/news/press-release-beyond-research-initiative-of-4sc-discovery-and-crelux-reaches-first-milestone-in-drug-discovery-project-for-helmholtz-zentrum-muenchen/ 2020-06-17T09:10:23+00:00 https://www.4sc.com/news/press-release-4scs-associated-company-panoptes-pharma-concludes-license-agreement-with-mediolanum-for-compound-pp-001-for-inflammatory-eye-diseases/ 2020-06-17T09:12:30+00:00 https://www.4sc.com/news/announcement-4sc-to-host-conference-call-on-25-march-2015-to-present-annual-results-2014/ 2020-06-17T09:14:36+00:00 https://www.4sc.com/news/press-release-4sc-publishes-results-for-financial-year-2014/ 2020-06-17T09:20:24+00:00 https://www.4sc.com/news/press-release-4sc-presents-new-immunotherapeutic-activity-data-of-its-epigenetic-cancer-drug-resminostat-at-the-ecco-itoc-conference-2015/ 2020-06-17T09:26:23+00:00 https://www.4sc.com/news/press-release-dr-susanne-danhauser-riedl-joins-4sc-as-chief-medical-officer-to-strengthen-management-and-clinical-development-team/ 2020-06-18T07:24:50+00:00 https://www.4sc.com/news/announcement-4sc-to-present-at-the-upcoming-kempen-co-life-sciences-conference/ 2020-06-18T07:26:58+00:00 https://www.4sc.com/news/press-release-4sc-signs-licensing-and-development-agreement-with-menarini-for-resminostat-in-asia-pacific-excluding-japan/ 2020-06-18T07:29:26+00:00 https://www.4sc.com/news/4sc-announces-implementation-of-51-reverse-share-split-in-line-with-planning/ 2020-06-18T07:31:32+00:00 https://www.4sc.com/news/announcement-4sc-ag-to-host-conference-call-on-7-may-2015-to-present-first-quarter-results-of-2015/ 2020-06-18T07:33:29+00:00 https://www.4sc.com/news/4sc-to-present-at-three-upcoming-investor-conferences/ 2020-06-18T07:36:40+00:00 https://www.4sc.com/news/press-release-4sc-announces-financial-results-for-the-first-quarter-of-2015/ 2020-06-18T07:39:15+00:00 https://www.4sc.com/news/press-release-4sc-presents-final-results-from-phase-i-aegis-trial-as-well-as-rationale-for-daily-dosing-scheme-of-4sc-205-cancer-compound-at-asco/ 2020-06-18T07:41:23+00:00 https://www.4sc.com/news/press-release-4scs-partner-yakult-honsha-enters-with-cancer-compound-resminostat-further-indications-and-starts-clinical-phase-i-study-in-patients-with-pancreatic-or-biliary-tract-cancer-in/ 2020-06-18T07:43:29+00:00 https://www.4sc.com/news/press-release-4sc-strengthens-patent-protection-for-lead-cancer-compound-resminostat/ 2020-06-18T08:09:54+00:00 https://www.4sc.com/news/press-release-4sc-ag-announces-formal-closing-of-capital-increase/ 2020-06-18T08:12:20+00:00 https://www.4sc.com/news/announcement-4sc-ag-to-host-conference-call-on-6-august-2015-to-present-second-quarter-results-of-2015/ 2020-06-18T08:14:54+00:00 https://www.4sc.com/news/press-release-4sc-announces-financial-results-for-the-first-half-of-2015/ 2020-06-18T08:17:47+00:00 https://www.4sc.com/news/press-release-4sc-strengthens-patent-protection-for-its-epigenetic-cancer-drug-candidate-4sc-202-in-growth-market-china/ 2020-06-18T08:19:55+00:00 https://www.4sc.com/news/announcement-4sc-to-present-at-the-upcoming-baader-investment-conference/ 2020-06-18T08:22:27+00:00 https://www.4sc.com/news/4sc-receives-funding-from-the-eurostars-programme-for-further-research-of-its-anti-cancer-agents-with-an-epigenetic-mode-of-action/ 2020-06-18T08:25:03+00:00 https://www.4sc.com/news/press-release-world-renowned-experts-in-the-field-of-cancer-therapy-development-discuss-epigenetic-regulation-of-immunogenicity-at-10th-4sc-scientific-symposium/ 2020-06-18T08:31:28+00:00 https://www.4sc.com/news/announcement-4sc-ag-to-host-conference-call-on-11-november-2015-to-present-third-quarter-results-of-2015/ 2020-06-18T08:33:37+00:00 https://www.4sc.com/news/press-release-4sc-announces-financial-results-for-the-first-nine-months-and-the-third-quarter-of-2015/ 2020-06-18T08:36:20+00:00 https://www.4sc.com/news/announcement-4sc-ag-to-present-at-two-upcoming-investor-conferences/ 2020-06-18T08:38:34+00:00 https://www.4sc.com/news/fda-approves-ind-application-for-resminostat-in-liver-cancer/ 2020-06-18T08:49:47+00:00 https://www.4sc.com/news/epigenetic-compound-4sc-202-strengthens-endogenous-immune-response-to-cancer/ 2020-06-18T08:54:35+00:00 https://www.4sc.com/news/conference-call-to-be-hosted-on-30-march-2016-to-present-annual-results-2015/ 2020-06-18T08:57:19+00:00 https://www.4sc.com/news/4sc-announces-results-for-financial-year-2015/ 2020-06-18T09:02:30+00:00 https://www.4sc.com/news/4sc-to-focus-on-development-of-epigenetics-clinical-programs-sells-operations-of-discovery-division/ 2020-06-18T09:07:01+00:00 https://www.4sc.com/news/conference-call-to-be-hosted-on-12-may-2016-to-present-q1-2016-interim-communication/ 2020-06-18T09:09:42+00:00 https://www.4sc.com/news/4sc-reports-on-key-events-in-q1-2016/ 2020-06-18T09:15:06+00:00 https://www.4sc.com/news/4sc-enters-into-licensing-and-development-partnership-with-link-health-for-the-cancer-compound-4sc-205-in-china/ 2020-06-18T09:18:05+00:00 https://www.4sc.com/news/4sc-at-asco-4sc-202-and-checkpoint-inhibitors-strong-partners-in-cancer-treatment/ 2020-06-18T09:20:59+00:00 https://www.4sc.com/news/resminostat-boosts-cancer-immunotherapy/ 2020-06-18T09:24:01+00:00 https://www.4sc.com/news/4sc-forms-international-scientific-expert-panel/ 2020-06-18T13:07:01+00:00 https://www.4sc.com/news/conference-call-to-be-hosted-on-11-august-2016-to-present-the-consolidated-half-year-financial-report-2016/ 2020-06-18T13:10:06+00:00 https://www.4sc.com/news/4sc-provides-operational-and-financial-update-for-q2-and-6m-2016/ 2020-06-18T13:13:15+00:00 https://www.4sc.com/news/epigenetics-reprogramming-cancer-overcoming-drug-resistance-11th-4sc-scientific-symposium/ 2020-06-18T13:17:31+00:00 https://www.4sc.com/news/dr-jason-loveridge-appointed-new-ceo-of-4sc-2/ 2020-06-18T13:20:07+00:00 https://www.4sc.com/news/4sc-sells-immunology-portfolio-to-immunic/ 2020-06-18T13:23:08+00:00 https://www.4sc.com/news/conference-call-to-be-hosted-on-10-november-2016-to-present-9m-2016-interim-communication/ 2020-06-18T13:26:12+00:00 https://www.4sc.com/news/4sc-provides-q3-2016-update/ 2020-06-18T13:29:57+00:00 https://www.4sc.com/news/first-patient-enrolled-in-pivotal-resmain-study-of-resminostat-in-ctcl/ 2020-06-18T13:32:55+00:00 https://www.4sc.com/news/overall-survival-benefit-for-resminostat-in-first-line-liver-cancer-study-subgroup/ 2020-06-18T13:43:57+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-11-august-2020-to-present-the-half-year-report-2020/ 2020-08-04T05:30:51+00:00 https://www.4sc.com/news/4sc-provides-q2-2020-and-h1-2020-update/ 2020-08-11T05:30:18+00:00 https://www.4sc.com/news/4sc-and-maruho-discontinue-collaboration-for-development-of-4scs-kv1-3-inhibitors/ 2020-09-11T05:30:29+00:00 https://www.4sc.com/news/4sc-ag-expands-avelumab-supply-agreement-with-merck-kgaa-darmstadt-germany-and-pfizer-for-further-clinical-combination-study-of-domatinostat-in-merkel-cell-carcinoma/ 2020-09-15T05:30:50+00:00 https://www.4sc.com/news/4sc-ag-poster-presentation-at-the-esmo-virtual-congress-2020/ 2020-09-17T05:30:10+00:00 https://www.4sc.com/news/4sc-ag-announces-publication-of-a-new-article-on-domatinostat/ 2020-09-28T05:30:59+00:00 https://www.4sc.com/news/4sc-ag-positive-safety-review-of-phase-ib-ii-emerge-study-of-domatinostat-avelumab-in-gastrointestinal-cancer-3/ 2020-10-06T05:30:10+00:00 https://www.4sc.com/news/4sc-ag-announces-availability-of-a-new-publication-on-domatinostat/ 2020-10-12T05:30:05+00:00 https://www.4sc.com/news/4sc-provides-q3-business-update-and-outlook-3/ 2020-10-20T05:30:47+00:00 https://www.4sc.com/news/first-patient-enrolled-in-merklin-2-study/ 2020-10-21T05:30:04+00:00 https://www.4sc.com/news/4sc-ag-resolves-to-issue-new-shares-with-expected-proceeds-of-approx-eur-7-5-million/ 2020-11-25T18:00:33+00:00 https://www.4sc.com/news/4sc-ag-7-upcoming-conferences/ 2021-02-25T06:30:26+00:00 https://www.4sc.com/news/4sc-ag-provides-results-for-financial-year-2020-and-outlook-for-2021/ 2021-03-23T06:30:55+00:00 https://www.4sc.com/news/4sc-ag-and-immunic-sign-agreement-regarding-the-settlement-of-royalty-obligations-for-immunics-lead-program-imu-838-2/ 2021-04-01T08:20:35+00:00 https://www.4sc.com/news/4sc-ag-and-immunic-sign-agreement-regarding-the-settlement-of-royalty-obligations-for-immunics-lead-program-imu-838/ 2021-04-01T08:21:51+00:00 https://www.4sc.com/news/4sc-to-present-at-the-virtual-european-biotech-investor-days-2021-conference/ 2021-04-08T05:30:02+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-20-april-2021-to-present-the-q1-report-2021/ 2021-04-13T05:30:12+00:00 https://www.4sc.com/news/4sc-to-present-at-the-virtual-10th-world-congress-of-melanoma-and-17th-eado-congress/ 2021-04-15T05:30:06+00:00 https://www.4sc.com/news/4sc-provides-q1-2021-update/ 2021-04-20T05:30:16+00:00 https://www.4sc.com/news/4sc-ag-plans-reduction-of-share-capital-through-a-reverse-split-of-shares/ 2021-05-06T16:15:15+00:00 https://www.4sc.com/news/4sc-to-present-results-from-the-sensitize-study-at-the-virtual-2021-asco-annual-meeting/ 2021-06-07T11:00:47+00:00 https://www.4sc.com/news/4sc-resminostat-and-resmain-study-update-2/ 2021-06-16T05:30:28+00:00 https://www.4sc.com/news/4sc-and-netherlands-cancer-institute-collaborate-on-clinical-evaluation-of-domatinostat-in-the-neoadjuvant-setting-in-urothelial-cancer/ 2021-06-17T05:30:08+00:00 https://www.4sc.com/news/bekanntmachung-ueber-die-herabsetzung-des-grundkapitals-nach-den-vorschriften-ueber-die-ordentliche-kapitalherabsetzung-nach-%c2%a7%c2%a7-222-ff-aktg-durch-zusammenlegung-von-aktien/ 2021-07-12T18:02:00+00:00 https://www.4sc.com/news/4sc-announces-implementation-of-51-reverse-share-split-as-previously-announced/ 2021-07-12T18:30:15+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-10-august-2021-to-present-the-half-year-report-2021/ 2021-08-03T05:30:07+00:00 https://www.4sc.com/news/4sc-provides-q2-2021-and-h1-2021-update/ 2021-08-10T05:30:26+00:00 https://www.4sc.com/news/4sc-ag-6-upcoming-conferences/ 2021-08-24T05:30:36+00:00 https://www.4sc.com/news/4sc-clinical-study-presentations-at-the-31-german-conference-of-skin-cancer-31-hautkrebskongress/ 2021-09-08T05:30:19+00:00 https://www.4sc.com/news/4sc-clinical-study-presentations-at-the-esmo-congress-2021/ 2021-09-16T05:30:18+00:00 https://www.4sc.com/news/first-patient-enrolled-in-turandot-study-evaluating-domatinostat-in-the-neoadjuvant-setting-in-urothelial-carcinoma/ 2021-10-04T14:39:17+00:00 https://www.4sc.com/news/4sc-to-present-at-the-eortc-cl-group-20-21-meeting/ 2021-10-14T05:30:43+00:00 https://www.4sc.com/news/4sc-provides-q3-highlights-and-financial-forecast/ 2021-10-19T06:45:29+00:00 https://www.4sc.com/news/4sc-ag-domatinostat-program-update/ 2021-10-26T08:00:07+00:00 https://www.4sc.com/news/4sc-recruitment-target-of-190-patients-now-reached-in-resmain/ 2021-11-08T06:30:44+00:00 https://www.4sc.com/news/4sc-more-than-80-of-events-now-reached-for-unblinding-of-resmain/ 2021-11-22T06:30:54+00:00 https://www.4sc.com/news/4sc-ag-discontinuation-domatinostat-program/ 2022-02-01T17:45:28+00:00 https://www.4sc.com/news/4sc-ag-discontinuation-domatinostat-program-2/ 2022-02-01T18:00:55+00:00 https://www.4sc.com/news/4sc-ag-provides-results-for-financial-year-2021-and-outlook-for-2022/ 2022-03-22T06:30:58+00:00 https://www.4sc.com/news/4sc-provides-q1-2022-update/ 2022-04-19T05:30:20+00:00 https://www.4sc.com/news/4sc-resminostat-and-resmain-study-update-3/ 2022-05-05T05:30:53+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-9-august-2022-to-present-the-half-year-report-2022/ 2022-08-02T05:30:41+00:00 https://www.4sc.com/news/4sc-provides-q3-highlights-and-financial-forecast-2/ 2022-10-18T05:30:34+00:00 https://www.4sc.com/news/kathleen-masch-wiest-is-new-member-of-the-management-board-of-4sc/ 2022-11-14T06:30:22+00:00 https://www.4sc.com/news/european-medicines-agency-accepts-4scs-eligibility-request-for-resminostat-in-cutaneous-t-cell-lymphoma-ctcl/ 2023-01-11T06:30:16+00:00 https://www.4sc.com/news/4sc-ag-provides-results-for-financial-year-2022-and-outlook-for-2023/ 2023-03-17T06:30:57+00:00 https://www.4sc.com/news/4sc-provides-q1-2023-update/ 2023-04-20T05:30:54+00:00 https://www.4sc.com/news/4sc-ag-resmain-trial-meets-primary-endpoint-in-cutaneous-t-cell-lymphoma-ctcl/ 2023-05-23T10:35:21+00:00 https://www.4sc.com/news/resminostat-4sc-filed-letter-of-intent-to-the-european-medicines-agency-ema/ 2023-05-31T05:30:01+00:00 https://www.4sc.com/news/4sc-ag-resminostat-marketing-application-proceeding-kinselby-accepted-as-tradename/ 2023-06-19T05:30:07+00:00 https://www.4sc.com/news/resmain-study-results-to-be-presented-at-the-eortc-cutaneous-lymphoma-tumour-group-annual-meeting-23-september-2023/ 2023-07-04T05:30:05+00:00 https://www.4sc.com/news/4sc-provides-q2-2023-and-h1-2023-update/ 2023-08-10T05:30:15+00:00 https://www.4sc.com/news/4sc-resmain-study-data-to-be-presented-at-the-eortc-cutaneous-lymphoma-tumour-group-annual-meeting/ 2023-09-15T05:30:33+00:00 https://www.4sc.com/news/4sc-landmark-resmain-study-data-presented-at-the-eortc-cutaneous-lymphoma-tumour-group-annual-meeting/ 2023-09-25T05:30:26+00:00 https://www.4sc.com/news/4sc-receives-orphan-drug-designation-odd-for-resminostat-kinselby-in-ctcl-from-the-us-fda/ 2023-09-27T05:30:48+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-19th-october-2023-to-present-the-q3-report-2023/ 2023-10-12T05:30:25+00:00 https://www.4sc.com/news/4sc-receives-orphan-drug-designation-odd-for-resminostat-kinselby-in-ctcl-in-the-european-union/ 2023-10-18T05:30:09+00:00 https://www.4sc.com/news/4sc-provides-q3-highlights-and-financial-forecast-3/ 2023-10-19T05:30:33+00:00 https://www.4sc.com/news/4sc-ag-notice-of-loss-pursuant-to-section-92-1-german-stock-corporation-act-aktiengesetz-aktg/ 2023-12-20T09:45:55+00:00 https://www.4sc.com/news/4sc-ag-company-update/ 2023-12-20T09:45:05+00:00 https://www.4sc.com/news/4sc-files-marketing-authorisation-application-with-ema-for-resminostat-kinselby/ 2024-03-01T09:00:57+00:00 https://www.4sc.com/news/4sc-ag-provides-results-for-financial-year-2023-and-outlook-for-2024/ 2024-03-22T06:30:59+00:00 https://www.4sc.com/news/4sc-landmark-resmain-study-data-presented-at-the-5th-world-congress-of-cutaneous-lymphomas/ 2024-04-11T05:30:23+00:00 https://www.4sc.com/news/4sc-ag-paediatric-investigation-plan-waiver-for-resminostat-from-the-uk-mhra-received/ 2024-04-15T05:30:27+00:00 https://www.4sc.com/news/4sc-publishes-q1-2024-report/ 2024-04-18T05:30:53+00:00 https://www.4sc.com/news/4sc-ag-agm-highlights-positive-progress-in-2023-2024-leaves-company-well-positioned-for-resminostat-kinselby-commercialisation/ 2024-06-20T14:15:00+00:00 https://www.4sc.com/news/4sc-receives-orphan-drug-status-ods-for-resminostat-kinselby-in-cutaneous-t-cell-lymphoma-in-switzerland/ 2024-07-16T05:30:45+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-8-august-2024-to-present-the-h1-report-2024/ 2024-08-01T05:30:22+00:00 https://www.4sc.com/news/4sc-announces-half-year-report-2024-and-provides-update/ 2024-08-08T05:30:18+00:00 https://www.4sc.com/news/4sc-ag-resolves-to-issue-new-shares-with-expected-proceeds-of-approx-eur-4-million/ 2024-09-11T15:40:35+00:00 https://www.4sc.com/news/4sc-publishes-q3-2024-report/ 2024-10-17T05:30:10+00:00 https://www.4sc.com/news/4sc-announces-update-relating-to-resminostats-kinselby-marketing-authorisation-application/ 2025-01-07T08:22:31+00:00 https://www.4sc.com/news/4sc-announces-emas-feedback-relating-to-resminostats-kinselby-marketing-authorisation-application/ 2025-03-03T10:55:06+00:00 https://www.4sc.com/news/4sc-announces-an-update-to-resminostats-kinselby-marketing-authorisation-application/ 2025-03-13T15:15:34+00:00 https://www.4sc.com/news/4sc-ag-provides-results-for-financial-year-2024-and-outlook-for-2025/ 2025-03-28T06:30:59+00:00 https://www.4sc.com/news/4sc-publishes-q1-2025-report-2/ 2025-04-17T05:30:33+00:00 https://www.4sc.com/news/4sc-announces-further-ema-feedback-relating-to-resminostats-kinselby-marketing-authorisation-application/ 2025-04-28T14:15:56+00:00 https://www.4sc.com/news/ema-signals-a-negative-chmp-opinion-on-the-marketing-authorization-application-for-resminostat-kinselby/ 2025-05-20T16:00:12+00:00 https://www.4sc.com/news/resminostat-kinselby-received-a-negative-chmp-opinion-in-the-eu/ 2025-05-23T15:00:16+00:00 https://www.4sc.com/news/capital-reduction-to-zero-and-simultaneous-cash-capital-increase-with-subscription-rights-planned/ 2025-07-23T08:15:56+00:00 https://www.4sc.com/news/4sc-publishes-half-year-report-2025/ 2025-08-12T09:26:51+00:00 https://www.4sc.com/news/4sc-ag-conference-call-to-be-hosted-on-17th-october-2025-to-present-the-q3-report-2025/ 2025-10-10T05:30:37+00:00 https://www.4sc.com/news/4sc-publishes-q3-report-2025/ 2025-10-17T05:30:11+00:00 https://www.4sc.com/news/implementation-of-the-capital-measures-resolved-by-the-2025-agm-is-expected-to-start-in-the-2nd-half-of-november-2025/ 2025-11-18T06:30:28+00:00 https://www.4sc.com/news/timely-implementation-of-the-capital-measures-expected-leading-to-the-expiry-of-all-old-shares-and-delisting/ 2025-12-12T06:30:48+00:00 https://www.4sc.com/news/4sc-ag-capital-reduction-to-zero-and-simultaneous-capital-increase-effective-delisting-from-the-frankfurt-stock-exchange/ 2025-12-16T11:30:19+00:00